GREENVILLE, S.C., June 26 /PRNewswire-FirstCall/ -- Signalife, Inc. announced today that it has received Industry Canada (IC) certification which allows the importation of the Signalife Fidelity 100 ECG Monitor System for marketing and sale into Canada. The certification states that the device is in compliance with the necessary requirements for medical devices of this type. Therefore, the Fidelity 100 may be marketed in, and legally imported from the United States into Canada.
Revenues for ECG devices in the Canadian market exceeded $200 million in 2006. Canada's health care system is a group of socialized health insurance plans that provides coverage to all Canadian citizens. It is publicly funded and administered on a provincial or territorial basis, within guidelines set by the federal government.
Under the Canadian health care system, individual citizens are provided preventative care and medical treatments from primary care physicians as well as access to hospitals, dental surgery and additional medical services. With a few exceptions, all citizens qualify for health coverage regardless of medical history, personal income, or standard of living.
Canada does boast one of the highest life expectancies (about 80 years) and lowest infant morality rates of industrialized countries, which many attribute to Canada's health care system.
"Approval to sell our product in Canada is another significant milestone for the company as the country's focus on preventative healthcare will be addressed by the signal quality of the Fidelity 100 and its ability to detect minimal cardiac problems at an early stage of the disease progression, thus arming physicians with better diagnostic data. The access to more accurate data may allow physicians to utilize various treatment options for patients before cardiovascular disease progresses to its most debilitating stages," states Pam Bunes, CEO of Signalife, Inc.
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance for heart monitoring and other biomedical devices incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical devices incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
Signalife, Inc.CONTACT: Kevin Kading of Signalife, Inc., +1-212-918-4606
Web site: http://www.signalife.com/
